

# Christopher R Mccurdy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1770618/publications.pdf>

Version: 2024-02-01

120  
papers

3,888  
citations

117625

34  
h-index

149698

56  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3199  
citing authors

#	ARTICLE	IF	CITATIONS
1	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. <i>Nature Medicine</i> , 2019, 25, 1938-1947.	30.7	348
2	Self-treatment of opioid withdrawal using kratom ( <i>Mitragynia speciosa korth</i> ). <i>Addiction</i> , 2008, 103, 1048-1050.	3.3	287
3	<i>Mitragynia speciosa</i> , A Psychoactive Tree from Southeast Asia with Opioid Activity. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1165-1175.	2.1	159
4	Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 83, 109-113.	2.9	109
5	Abuse liability and therapeutic potential of the <i>Mitragynia speciosa</i> (kratom) alkaloids mitragynine and 7-hydroxymitragynine. <i>Addiction Biology</i> , 2019, 24, 874-885.	2.6	103
6	Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. <i>Journal of Medical Toxicology</i> , 2016, 12, 341-349.	1.5	93
7	Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 433-439.	6.4	92
8	The Sigma-2 Receptor and Progesterone Receptor Membrane Component 1 are Different Binding Sites Derived From Independent Genes. <i>EBioMedicine</i> , 2015, 2, 1806-1813.	6.1	84
9	Kratom policy: The challenge of balancing therapeutic potential with public safety. <i>International Journal of Drug Policy</i> , 2019, 70, 70-77.	3.3	83
10	New Positron Emission Tomography (PET) Radioligand for Imaging $\beta$ -1 Receptors in Living Subjects. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8272-8282.	6.4	81
11	Analgesic substances derived from natural products (natureceuticals). <i>Life Sciences</i> , 2005, 78, 476-484.	4.3	78
12	Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of <i>Mitragynia speciosa</i> (kratom). <i>Xenobiotica</i> , 2019, 49, 1279-1288.	1.1	70
13	The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. <i>Journal of Biological Chemistry</i> , 2017, 292, 11250-11261.	3.4	69
14	Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 62, 197-211.	4.0	66
15	Herbal Medicines for the Management of Opioid Addiction. <i>CNS Drugs</i> , 2011, 25, 999-1007.	5.9	64
16	<i>N</i> -naphthoyl- $\beta$ -naltrexamine (NNTA), a highly selective and potent activator of $\mu$ -opioid heteromers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5098-5103.	7.1	63
17	Simultaneous quantification of ten key Kratom alkaloids in <i>Mitragynia speciosa</i> leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2019, 11, 1162-1171.	2.6	62
18	Patterns and reasons for kratom ( <i>Mitragynia speciosa</i> ) use among current and former opioid poly-drug users. <i>Journal of Ethnopharmacology</i> , 2020, 249, 112462.	4.1	61

#	ARTICLE	IF	CITATIONS
19	Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2. Medicinal Chemistry Research, 2014, 23, 4295-4300.	2.4	56
20	Determination of mitragynine in rat plasma by LC-MS/MS: Application to pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2593-2597.	2.3	52
21	Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for $\mu$ -Opioid Receptor and Opioid-Like Behavioral Effects in Rats. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 410-427.	2.5	52
22	Conversion of a Highly Selective Sigma-1 Receptor Ligand to Sigma-2 Receptor Preferring Ligands with Anticocaine Activity. Journal of Medicinal Chemistry, 2008, 51, 1482-1486.	6.4	50
23	SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Experimental Neurology, 2014, 254, 180-189.	4.1	47
24	Development of Cannabinoids in Flowers of Industrial Hemp ( <i>Cannabis sativa</i> L.): A Pilot Study. Journal of Agricultural and Food Chemistry, 2020, 68, 6058-6064.	5.2	47
25	Visualizing Nerve Injury in a Neuropathic Pain Model with $^{18}\text{F}$ -FTC-146 PET/MRI. Theranostics, 2017, 7, 2794-2805.	10.0	46
26	Exploring the Chemistry of Alkaloids from Malaysian <i>Mitragyna speciosa</i> (Kratom) and the Role of Oxindoles on Human Opioid Receptors. Journal of Natural Products, 2021, 84, 1034-1043.	3.0	45
27	Evaluation of $^{18}\text{F}$ -1 Receptor Radioligand $^{18}\text{F}$ -FTC-146 in Rats and Squirrel Monkeys Using PET. Journal of Nuclear Medicine, 2014, 55, 147-153.	5.0	44
28	Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology, 2017, 234, 2597-2605.	3.1	43
29	Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 6523-6548.	6.4	42
30	Motives for using Kratom ( <i>Mitragyna speciosa</i> Korth.) among regular users in Malaysia. Journal of Ethnopharmacology, 2019, 233, 34-40.	4.1	41
31	The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. Psychopharmacology, 2019, 236, 2725-2734.	3.1	40
32	Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence. Drug and Alcohol Dependence, 2020, 216, 108310.	3.2	40
33	Comparative Pharmacokinetics of Mitragynine after Oral Administration of <i>Mitragyna speciosa</i> (Kratom) Leaf Extracts in Rats. Planta Medica, 2019, 85, 340-346.	1.3	36
34	Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicology Letters, 2020, 319, 148-154.	0.8	36
35	Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy. ACS Pharmacology and Translational Science, 2020, 3, 1063-1068.	4.9	36
36	Phytochemical characterization of the leaves of <i>Mitragyna speciosa</i> grown in U.S.A. Natural Product Communications, 2009, 4, 907-10.	0.5	36

#	ARTICLE	IF	CITATIONS
37	Synthesis and Pharmacological Evaluation of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a Cocaine Antagonist, in Rodents. <i>AAPS Journal</i> , 2011, 13, 336-346.	4.4	35
38	Biodistribution and Radiation Dosimetry of $^{18}\text{F}$ -FTC-146 in Humans. <i>Journal of Nuclear Medicine</i> , 2017, 58, 2004-2009.	5.0	34
39	Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo. <i>AAPS Journal</i> , 2020, 22, 94.	4.4	33
40	Sigma Receptors and Cocaine Abuse. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1128-1150.	2.1	32
41	A Novel Substituted Piperazine, CM156, Attenuates the Stimulant and Toxic Effects of Cocaine in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 491-500.	2.5	31
42	Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain. <i>Frontiers in Pharmacology</i> , 2019, 10, 678.	3.5	31
43	Activity of <i>Mitragyna speciosa</i> (‘Kratom’) Alkaloids at Serotonin Receptors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13510-13523.	6.4	30
44	Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats. <i>Journal of Natural Products</i> , 2021, 84, 1104-1112.	3.0	29
45	Simple, Sensitive, High-Throughput Method for the Quantification of Mitragynine in Rat Plasma Using UPLC-MS and Its Application to an Intravenous Pharmacokinetic Study. <i>Chromatographia</i> , 2011, 74, 703-710.	1.3	28
46	Blockade of Cocaine or $\sigma$ Receptor Agonist Self Administration by Subtype-Selective $\sigma$ Receptor Antagonists. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 109-124.	2.5	27
47	Benzimidazolone-based selective $\sigma_2$ receptor ligands: Synthesis and pharmacological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 165, 250-257.	5.5	26
48	Radiosynthesis and First-In-Human PET/MRI Evaluation with Clinical-Grade $^{18}\text{F}$ FTC-146. <i>Molecular Imaging and Biology</i> , 2017, 19, 779-786.	2.6	25
49	Synthesis and pharmacological evaluation of antioxidant chalcone derivatives of 2(3H)-benzoxazolones. <i>Medicinal Chemistry Research</i> , 2009, 18, 467-476.	2.4	23
50	Further validation to support clinical translation of $^{18}\text{F}$ FTC-146 for imaging sigma-1 receptors. <i>EJNMMI Research</i> , 2015, 5, 49.	2.5	23
51	Design, synthesis and biological evaluation of bivalent benzoxazolone and benzothiazolone ligands as potential anti-inflammatory/analgesic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3248-3259.	3.0	23
52	Assessing the therapeutic potential and toxicity of <i>Mitragyna speciosa</i> in opioid use disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 255-257.	3.3	23
53	Novel 2(3H)-Benzothiazolones as Highly Potent and Selective Sigma-1 Receptor Ligands. <i>Medicinal Chemistry Research</i> , 2005, 14, 158-168.	2.4	21
54	WILLGERODT-KINDLER'S MICROWAVE-ENHANCED SYNTHESIS OF THIOAMIDE DERIVATIVES. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2004, 179, 1959-1973.	1.6	20

#	ARTICLE	IF	CITATIONS
55	Phytochemical Characterization of the Leaves of <i>Mitragyna Speciosa</i> Grown in USA. Natural Product Communications, 2009, 4, 1934578X0900400.	0.5	20
56	Kratom use as more than a "self-treatment". American Journal of Drug and Alcohol Abuse, 2022, 48, 684-694.	2.1	20
57	Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. Planta Medica, 2020, 86, 1278-1285.	1.3	19
58	Evaluation of the rewarding effects of mitragynine and 7 $\alpha$ -hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug and Alcohol Dependence, 2020, 215, 108235.	3.2	19
59	Kratom ( <i>Mitragyna speciosa</i> ): worldwide issues. Current Opinion in Psychiatry, 2020, 33, 312-318.	6.3	19
60	Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories. Frontiers in Pharmacology, 2022, 13, 765917.	3.5	19
61	Naphthalene Dicarboxaldehyde as an Electrophilic Fluorogenic Moiety for Affinity Labeling: Application to Opioid Receptor Affinity Labels with Greatly Improved Fluorogenic Properties. Journal of Medicinal Chemistry, 2002, 45, 2887-2890.	6.4	18
62	Synthesis and Pharmacological Characterization of a Novel Sigma Receptor Ligand with Improved Metabolic Stability and Antagonistic Effects Against Methamphetamine. AAPS Journal, 2012, 14, 43-51.	4.4	18
63	Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 203-212.	2.5	18
64	Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[ <i>d</i> ]oxazol-2(3 <i>H</i> )-one (SN79) Derivatives. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 272-281.	2.5	18
65	In vitro opioid receptor affinity and in vivo behavioral studies of <i>Nelumbo nucifera</i> flower. Journal of Ethnopharmacology, 2015, 174, 57-65.	4.1	17
66	A Role for Sigma Receptors in Stimulant Self-Administration and Addiction. Handbook of Experimental Pharmacology, 2016, 244, 177-218.	1.8	17
67	Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 434-445.	2.5	17
68	Effects of Nutrient Fertility on Growth and Alkaloidal Content in <i>Mitragyna speciosa</i> (Kratom). Frontiers in Plant Science, 2020, 11, 597696.	3.6	17
69	Slow conformational dynamics of the human A2A adenosine receptor are temporally ordered. Structure, 2022, 30, 329-337.e5.	3.3	17
70	Flavanones from <i>Miconia prasina</i> . Phytochemistry Letters, 2014, 7, 130-132.	1.2	16
71	Investigation of Phenolic Bioisosterism in Opiates: 3-Sulfonamido Analogues of Naltrexone and Oxymorphone. Organic Letters, 2000, 2, 819-821.	4.6	15
72	Ultra-performance liquid chromatography tandem mass spectrometry method for the determination of AZ66, a sigma receptor ligand, in rat plasma and its application to <i>in vivo</i> pharmacokinetics. Biomedical Chromatography, 2013, 27, 1034-1040.	1.7	14

#	ARTICLE	IF	CITATIONS
73	Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists. <i>Molecules</i> , 2018, 23, 2630.	3.8	14
74	Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 180, 113019.	2.8	14
75	Adolescent nicotine and tobacco smoke exposure enhances nicotine self-administration in female rats. <i>Neuropharmacology</i> , 2020, 176, 108243.	4.1	14
76	<i>In vitro</i> and <i>in vivo</i> sigma 1 receptor imaging studies in different disease states. <i>RSC Medicinal Chemistry</i> , 2021, 12, 154-177.	3.9	14
77	Potential independent action of sigma receptor ligands through inhibition of the Kv2.1 channel. <i>Oncotarget</i> , 2017, 8, 59345-59358.	1.8	14
78	<i>In vitro</i> and <i>in vivo</i> pharmacology of kratom. <i>Advances in Pharmacology</i> , 2022, 93, 35-76.	2.0	13
79	Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a mu-opioid agonist, in rat plasma and its application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2013, 27, 1726-1732.	1.7	12
80	Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells. <i>Pathogens</i> , 2021, 10, 1514.	2.8	12
81	Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. <i>Molecules</i> , 2022, 27, 3617.	3.8	12
82	The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study. <i>Drug Metabolism and Disposition</i> , 2022, 50, 158-167.	3.3	11
83	Plant growth and phytoactive alkaloid synthesis in kratom [ <i>Mitragyna speciosa</i> (Korth.)] in response to varying radiance. <i>PLoS ONE</i> , 2022, 17, e0259326.	2.5	11
84	Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. <i>Drug Testing and Analysis</i> , 2017, 9, 1236-1242.	2.6	10
85	Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 194, 113778.	2.8	10
86	Synthesis and characterization of [3H]-SN56, a novel radioligand for the 5f1 receptor. <i>European Journal of Pharmacology</i> , 2011, 653, 1-7.	3.5	9
87	Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine <i>in vitro</i> . <i>European Journal of Pharmacology</i> , 2014, 724, 193-203.	3.5	9
88	Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy. <i>Scientific Reports</i> , 2021, 11, 17150.	3.3	9
89	Health Effects Associated With Kratom ( <i>Mitragyna speciosa</i> ) and Polysubstance Use: A Narrative Review. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182210958.	0.9	9
90	Regulatory sampling of industrial hemp plant samples ( <i>Cannabis sativa</i> L.) using UPLC-MS/MS method for detection and quantification of twelve cannabinoids. <i>Journal of Cannabis Research</i> , 2020, 2, 42.	3.2	8

#	ARTICLE	IF	CITATIONS
91	Need for Clarity and Context in Case Reports on Kratom Use, Assessment, and Intervention. Substance Abuse, 2022, 43, 1221-1224.	2.3	8
92	Unsymmetrical Diarylketones from Electron-rich Heterocyclic Arenes. Monatshefte für Chemie, 2003, 134, 823-830.	1.8	7
93	Evaluation of <sup>18</sup> F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration <i>in vivo</i> in rodents and in human tissue. Theranostics, 2020, 10, 7938-7955.	10.0	7
94	Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one $\sigma_1$ receptor ligands. Medicinal Chemistry Research, 2020, 29, 1697-1706.	2.4	6
95	Identification and characterization of MAM03055A: A novel bivalent sigma-2 receptor/TMEM97 ligand with cytotoxic activity. European Journal of Pharmacology, 2021, 906, 174263.	3.5	6
96	The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats. Journal of Pharmacological and Toxicological Methods, 2021, 111, 107101.	0.7	6
97	Chiral separation of lobeline analogs using high performance capillary electrophoresis and derivatized cyclodextrins as chiral additives. Electrophoresis, 1999, 20, 212-218.	2.4	5
98	Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand. Journal of Pharmaceutical and Biomedical Analysis, 2020, 191, 113610.	2.8	5
99	Current and Future Potential Impact of COVID-19 on Kratom ( <i>Mitragyna speciosa</i> Korth.) Supply and Use. Frontiers in Psychiatry, 2020, 11, 574483.	2.6	5
100	Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors. Biomedicines, 2021, 9, 1304.	3.2	5
101	Potential Contribution of 7-Hydroxymitragynine, a Metabolite of the Primary Kratom ( <i>Mitragyna speciosa</i> ) to the Opioid Receptor Mediated Effects of Kratom. Journal of Ethnopharmacology, 2021, 270, 113414.	0.5	5
102	The Adrenergic $\alpha_2$ Receptor-Mediated Discriminative Stimulus Effects of Mitragynine, the Primary Alkaloid in Kratom ( <i>Mitragyna speciosa</i> ) in Rats. FASEB Journal, 2020, 34, 1-1.	0.5	5
103	Development of Opioid Receptor Ligands. , 2006, , 259-276.		4
104	Design and synthesis of 3-acyl-2(3H)-benzoxazolone and 3-acyl-2(3H)-benzothiazolone derivatives. Monatshefte für Chemie, 2011, 142, 67-80.	1.8	4
105	Structure-activity relationship of phenytoinergic antiepileptic drugs related to ameltolide. Medicinal Chemistry Research, 2007, 16, 130-135.	2.4	3
106	Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 459-463.	1.6	3
107	Acute morphine blocks spinal respiratory motor plasticity via long-latency mechanisms that require toll-like receptor 4 signalling. Journal of Physiology, 2021, 599, 3771-3797.	2.9	3
108	Sigma-1 Receptor Changes Observed in Chronic Pelvic Pain Patients: A Pilot PET/MRI Study. Frontiers in Pain Research, 2021, 2, 711748.	2.0	3



#	ARTICLE	IF	CITATIONS
109	Is cocaine a social drug? Exploration of the stereo-structure of cocaine's pharmacophore. Medicinal Chemistry Research, 2013, 22, 247-252.	2.4	2
110	Insight into the Willgerodt-Kindler Reaction of $\alpha$ -Haloacetophenone Derivatives: Mechanistic Implication. Organic Chemistry International, 2014, 2014, 1-5.	1.0	2
111	Characterization of a mouse neuropathic pain model caused by the highly active antiviral therapy (HAART) Stavudine. Pharmacological Reports, 2021, 73, 1457-1464.	3.3	1
112	SN79, a sigma receptor ligand, mitigates methamphetamine-induced astrocyte and microglial activation. FASEB Journal, 2013, 27, 1175.2.	0.5	1
113	2007 highlights of advances in the pharmaceutical sciences: An American Association of Pharmaceutical Scientists (AAPS) perspective. AAPS Journal, 2007, 9, E219-E226.	4.4	0
114	The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360. AAPS PharmSciTech, 2018, 19, 3325-3327.	3.3	0
115	Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1134-1135, 121875.	2.3	0
116	The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360. AAPS Journal, 2019, 21, 2.	4.4	0
117	Pharmacological Characterization of Mitragynine, the Primary Constituent in Kratom ( Mitragyna) Tj ETQq1 1 0.784314 rgBT 0 Overload	0.5	0
118	Editorial: The Pharmacology of Kratom and Its Alkaloids. Frontiers in Pharmacology, 2022, 13, 878376.	3.5	0
119	UPLC-MS/MS method for the quantification of MCI-77, a novel sigma-1 receptor ligand, and its application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1196, 123187.	2.3	0
120	Effects of Mitragynine and its Active Metabolites on the Reinforcing Effects of Remifentanil and Cocaine in Rats Self-Administering Remifentanil. FASEB Journal, 2022, 36, .	0.5	0